PCR, a gold-standard diagnostic method, were labor-intensive, time-consuming,costly, which restricted its application to widespread screening. Herein, this study purposes a one-potnon-washing method to rapidly detect virus by dual-SERS mechanism. COVID Antigens were captured by SERS nanoparticlesnovel SERS substrate simultaneously to achieve 6 order enhancements within 20 minutes. The dual-SERS sensors have reached a detection limit of 1 ng/ml in clinical samples for recognizing nucleocapsid & Spike proteins of COVID-19, which is comparable with PCR results.

In this project, we have reorganized several highly immunogenic sitesstructurally essential regions to maintain it in a pre-fusion stateuse it as main antigen in our RSV vaccine candidate (RSV-F005). To induce a mucosal immune response, intranasal administration route was chosen. New mucosal adjuvant (H-muad) has been tested in threee animal models.

Gene delivery technology is widely used in cell therapy, nucleic acid-based vaccines, protein production, gene therapy, etc. We have developed a non-viral gene delivery technology-MPGene, which has excellent gene delivery efficiency (50-80) for human mesenchymal stem cells,also has the characteristics of low production costhigh safety. In the future, MPGene has the potential to be used in important biomedical fields such as gene delivery reagents, major trauma cell therapy, malignant tumor treatmentcartilage cell therapy.

With the use of E. coli expression system, capsid protein assembly in vitro, X-ray photoprotein crystallographycryo-electron microscope, the T=3 capsid structure of white tail disease viruses for shrimps has been resolved successfully, such that an entire model for capsid structure of virus could be provideda mechanism for viral assemblyinfection could be understood.

Vaccination is the most effective way to prevent influenza viruses infection. The egg-based production method has many drawbacks, we established baculovirus-based VLPs expression platform for H7N9 VLPs production, purify the VLPs satisfied with FDA regulation,improved its immunogenicity to the same level compared with H7N9 whole virus vaccine.

Two COVID-19 animal models, including humanized Ace2 micehuman peripheral blood lymphocyte transplanted mice, are used to mimic COVID-19 infection, immune responsecytokine release syndrome in human. The immune analytical platform can further outline the immune cell, cytokinebiomarker response pattern after viral infection. The COVID-19 humanized animal modelthe immune analytical platform will support COVID-19 related researchfacilitate new drugnew therapy validation.

The developed multi-functional bio-sensor chip has the advantages of excellent detection performance, wide application,low mass production. At present, we have already cooperated with upstreamdownstream manufacturers for mass production of the multifunctional bio-sensor chips. At the same time, cooperate with the instrument manufacturer to develop a simple portable electrochemical detect

We developed a recombinant adenovirus Ad-HFMD vaccine which can express virus-like particles (VLPs) of EV71 capsid proteins. Mouse studies showed that Ad-HFMD can induce the protective antibodycellular immunity against EV71CVA16 in hSCARB2 transgenic (hSCARB2-Tg) mouse challenge model.

BPRSJ338 exhibits high potency of anti-SARS-CoV-2 activity and is in development for fighting COVID-19 as a first-in-class drug. BPRSJ338 also potently inhibits against broad-spectrum coronaviruses including SARS-CoV-2, SARS-CoV, HCoV-229E, HCoV-OC43, TGEV, FIPV and MHV. Related US and Taiwan patents have been granted.​ Therefore it is also applicable to fight against severe evolving coronaviruses in the future.

Monoglycosylated spike protein vaccine provides better protection against infections of SARS-CoV-2its variants of concern. Spike protein, which is the main immunogen in all current vaccines, is heavily glycosylatedthe epitopes covered by glycans are usually less immunogenic. Monoglycosylated spike protein vaccine, when vaccinated, can elicit better immune response with a more complete protection against all possible epitopes from spike polypeptide sequence,provide better protection against infections from variants of concerns.

We provide antibody-based solutions to human diseases with short development course at low cost, are based on the phage-displayed GH (Generic Human) synthetic antibody libraries designedconstructed with enabling approaches, leading to the throughput capacities to uplift the innovativenessproductivity in developing antibody therapeuticsdiagnostics. In conjunction with the core technologies, antibody bioinformatics capable of extracting knowledge from big data of human antibody repertoires is used to elucidate human antibody responsesto assist antibody library design.

Our core generated several types of transgenic micea stable humanized ACE2 mice using a combi-CRISPR genetic engineering technique. We hope these mouse models can help to dissect COVID-19 pathogenic mechanismthe interaction(s) between spike proteinACE2 K353.

A high-sensitivity quantitative ELISA detection system for the large HBV surface (LHBS) protein was developed. It includes monoclonal antibodies for LHBSchemiluminescent sandwich ELISA method. Clinical tests of the ELISA prodcuts have been performed in CHB cases. The LHBS detection methodsproducts have been filed for US provisional patentwill be submitted for the IVD approval.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected human cell through ACE2. This study is developing a Pd nano-thin film electrode for electrochemical impedance spectroscopy. This invention can quantify neutralize antibody too. The detection platform can be used to screen 1 microliter anti-virus infection drug sample within 21 mins. Compare to SPR standard, our invention only needs 1/10000 concentration of ACE2reaction volume is ~1/30 than SPR. This invention can be adapted in detection of cancer markers,other emergency infection diseasestherapeutic drugs, too.

A virus NT was performed in a biosafety level 3 laboratory to determine the titers. A SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) was designed to detect neutralizing antibodies in the serum, based on the binding affinity of SARS-CoV-2 viral protein 1viral protein 2 to antibodies. ELISA results viral protein 12, generated comparable neutralizing antibody titers. The results analyzed by spline regressiontwo-variable generalized additive model precisely reflected the real NT value. Our method can serve as a surrogate to quantify neutralizing antibody titer.

We developed a chicken mucosa-targeting polymeric nanoparticle vaccine (~90 nm) co-delivering viral antigenCpG adjuvant using a water-in-oil-in-water double emulsion technique. The particles are biodegradablebiocompatible. This nanoparticle significantly stimulated chicken Harderian gland B cell proliferationsubsequent local IgAIgG secretion in tears. The mucosal Ig protected chickens from virus infection by lowering virus replication at the infection sitethereafter reducing tracheal epithelial ciliostasissystemic infection, relieving clinical symptoms.

NRICM101 has revealed positive outcome in COVID-19 treatment clinically. Pharmacological studies have confirmed that it can neutralize the SARS-CoV-2, block virus infection, inhibit virus growth,reduce the occurrence of cytokine storms. NRICM101 has been non-exclusively authorized by 8 Taiwanese GMP-certified TCM pharmaceuticals. At present, NRICM101 is seeing an increasing worldwide demand,has received Emergency Use Authorization from the Ministry of HealthWelfare of Taiwan. Asymptomaticmildly ill patients of COVID-19 are expected to benefit from it.

As we continue to face the rapid increase in confirmed Coronavirus cases around the world, we created an AI-based pneumonia detection platform for COVID-19. The system is able to automatically detect high-risk patients with pneumonia that will then send information to doctors. With that information, the doctors are then able to make follow-up decisions and provide a treatment plan after the diagnosis. In specific, doctors from the Department of Medical Imaging provided us thousands of positive and negative chest x-rays for pneumonia as a training set. Our system has already been tested with and adopted by doctors at the NCKU Hospital. The system achieved 95% accuracy to detect the pneumonia symptom, based on 1400 test images.

A method of enhancing a mammalian immune response to a virus is disclosed. The method comprises administering a composition comprising an effective amount of epinecidin (Epi)-1the virus to a mammal, wherein the virus has envelope proteinis infectious to the mammal. In this technique, Epi-1Japanese encephalitis virus (JEV) were mixedinjected into mice. The mice were infected with JEV 14 days later,all mice survived. This technology has also been verified in the preparation of vaccines for foot-and-mouth disease virusnervous necrosis virus.

By the help of the High Throughput Core Facility of the Genome Center of the Academia Sinica, potential drugs with activity are screened out,the P3 laboratory conducts the antiviral cell experiment of the drug to accurately determine the effect of inhibiting the virus. In addition, the production process of the antiviral drug "Remdesivir" is improved,innovative preparation methods are proposed, which greatly increase the yield of "Remdesivir"effectively reduce the manufacturing cost.

Provided is an influenza mucosal vaccine compositionpreparationapplication thereof. This composition contains an antigen fusion protein which includes an influenza virus antigena Type IIb heat-labile enterotoxin A subunit. Immunization with the antigen fusion protein induces cellularhumoral immune responses, including systemicmucosal immune responses, against a specific in

We have displayed AChE on insect cell membrane for the detection of OPCB pesticide residue. Compared to GC-MSLC-MS analysis, the cost of our system is much lower with time-saving comparing with conventional biochemical detection method, the enzyme extractionpurification from flies is not necessary in our system. Therefore, this is a fast, accurateeconomical choice for residue screening.

Due to the recent outbreak of COVID-19ongoing mutants, we developed a coronavirus variant protein microarray that includes all the current spike mutationsthe wild-type viral antigensapplied in detecting immune responsesdrug specificities. We filed the patientspublished our findings in the Analytical Chemistry. Besides massive production of the coronavirus protein microarray, we also collaborated with a scanner company, developed artificial intelligence software,collaborated with suppliers. We are welcome any sort of collaboration.

The "Herbmedotcin" technology platform is a major breakthrough in the several thousand years history of herbal medicine knowledge. Use patented technology to find potential natural functional molecules, with appropriate additivesoptimal processing conditions, to achieve a significant increase in their efficacy. This technology is also known as "molecular herbology". They h

Based on the optical fluorescence of the plant, the technology distinguishes the difference of the main protein infected by virus from the normal ones with the feature light. The main difference of this technology is to omit the complicatedbiochemical-material- consumption procedures. With the establishment of big data, the artificial intelligence algorithm identifies whether the implant is.

We propose an AI dynamics drug repurposing platform applicate on COVID-19. This platform analyzed a large number of structures of SARS-CoV, MERS,cross-species coronavirus 3CL protease-ligand complexes to construct uncovering six flexible active site conformationspharmacophore clusters for SARS-CoV-2 3CL protease screening all FDA drugsfound four inhibitors within three months. Among them, JM206 had even demonstrated ten times better efficacy than Remdesivir in-vitro assayalso show the effect on the in-vivo hamster model to alleviate the symptoms caused by COVID-19.

"We present here a portable device with isothermally mediated loop amplification (LAMP) for the diagnosis of infectious diseases. The main components included (1) roller conveyor, (2) hotplate,(3) temperaturemotion control panels. After mixing all the solutions by rollingsqueezing the sealed compartments, the LAMP strip was heated for 30 min for amplification. Finally, fluorescence results can be read with the naked eyeon a smartphone under the UV lamp. The 700g device is powered by a portable charger, making it easier to detect pathogens in resource-limited environments."

SeraParma™ COVID-19 IgM rapid test has high detection sensitivity, which can provide rapid detection of early COVID-19 infection. This SeraParma™ COVID-19 IgM rapid test can detect whether there are IgM antibodies produced in the early stage of infection (within 7 days of symptoms onset) with one drop of the specimen (serumfingertip blood) in 15 minutes by naked eyes compared with LFIA antibody rapid test. It is worth noting that the SeraParma™ COVID-19 IgM rapid test can accurately detect the patients with positive infection within 7 days of the onset of symptoms compared with LFIA.

This technology is a new microarray chip sensing technology that integrates "organic light-emitting diodes", "liquid crystal chemical sensors" and "mobile communication system" into "multifunctional liquid crystal smart cloud sensors". The obtained signals are uploaded to the cloud for multi-dimensional analysis to achieve multiplex detection in one single sample. This sensor device is lightweight, low-cost, simple to operate, and the target-of-interest can be custom-made according to user needs.

Effectively inducing cytotoxic T cell expansion has been a critical challenge in vaccine development. To address this challenge, an entirely biodegradable polymeric nanoshell was invented to couple antigensadjuvants for safepotent immune potentiation. The invention has been adopted for precision anticancer vaccine, broadly reactive influenza vaccine,an effective vaccine MERS-CoV.